Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pyxis Oncology (PYXS) Payables (2024 - 2025)

Pyxis Oncology (PYXS) has disclosed Payables for 2 consecutive years, with $9.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Payables rose 100.33% to $9.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was $9.8 million, a 100.33% increase, with the full-year FY2024 number at $4.9 million, changed N/A from a year prior.
  • Payables was $9.8 million for Q3 2025 at Pyxis Oncology, up from $9.4 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $9.8 million in Q3 2025 to a low of $2.3 million in Q1 2024.